Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511196 · ClinicalTrials.gov registry record · Early Phase 1
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03511196 is a Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03511196, a Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Adaptive Androgen Deprivation Therapy (ADT)
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511196
The ClinicalTrials.gov registry entry for NCT03511196 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.
NCT03511196 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03511196 about?
NCT03511196 is a clinical study titled "Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer". Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).
What is the current status of trial NCT03511196?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2018-09-17. Estimated completion is 2026-09.
What conditions does trial NCT03511196 study?
This clinical trial studies the following conditions: Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Advanced Prostate Cancer.
What interventions are being tested in trial NCT03511196?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), Adaptive Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT03511196?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511196 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.